Senate health bill pharma-friendly on biologics, price controls

Share this article:
The Senate health reform bill would maintain the ban on price controls in the Medicare prescription drug benefit and establish a 12-year data exclusivity period for biologics.

Like its House counterpart, the Senate's Patient Protection and Affordable Care Act establishes a pathway for approval of so-called biosimilars, or generic biologics. And as with the House legislation, the Senate version grants manufacturers of innovator drugs 12 years of data exclusivity, meaning that makers of biosimilars cannot piggyback on the innovator's clinical trials data until 12 years after the innovator's approval.

That sets a higher bar for biosimilars than is faced by generics, because within that 12-year window, the makers of biosimilars must conduct their own costly clinical trials in order to launch a challenger.

The Senate bill also grants biologics marketed for the treatment of rare disorders 7 years market exclusivity, extending the same protection granted small molecule compounds under the Orphan Drug Act. Companies can file for ordinary biosimilars 4 years after approval of the innovator product.

Unlike the House bill, the Senate bill does not authorize direct government negotiation of drug prices for the Medicare prescription drug benefit – a provision that PhRMA and AstraZeneca's David Brennan have called a deal-breaker. Language to that effect, contained in the House bill, would obviate the non-interference clause established in original Medicare Part D legislation.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.